Let's Think Long Term about Diabetes

We're pioneering an Implantable Glucose Sensor to empower the next generation of diabetes care. 

Our Commitment

The incidence of Diabetes is growing at a staggering pace so we are working hard for a healthier world.
Approximately 31 million Americans (9.4% of the population) have diabetes and as many as 1.5 million currently live with type 1, insulin-dependent diabetes (1).
Diabetes currently affects more than 463 million people globally and expected to exceed 700 million people by 2045 (2).
Diagnosed diabetes results in a total cost of $327 billion to the U.S. economy, driven largely by hospital inpatient care and prescription medications (3).
25% of the U.S. population aged 65 or older have diabetes along with nearly 200,000 children are estimated to have diagnosed diabetes (1).
Diabetes is a major cause of heart disease, stroke, kidney disease, blindness, and numerous other debilitating diseases and afflictions. It is the seventh leading cause of death in the U.S. (1).
Meet the Leadership

Development Status

The Eclipse 3 System is currently under development and is not yet approved, cleared, or otherwise available for commercial or public distribution. The system is currently undergoing clinical evaluation; initial human implant trials have been completed and preparations for additional human trials are underway.
1. Centers for Disease Control and Prevention. “National Diabetes Statistics Report 2017: Estimates of Diabetes and Its Burden in the United States, 2017.” Atlanta, GA: U.S. Department of Health and Human Services; 2017.
2. International Diabetes Federation. “IDF Diabetes Atlas 9th Edition“. Ninth edition published 2019
3. American Diabetes Association. "Economic Costs of Diabetes in the U.S. in 2017." Diabetes Care May 2018, 41 (5) 917-928; DOI: 10.2337/dci18-0007

3931 Sorrento Valley Blvd
Suite 110
San Diego, CA 92121

Ph:  +1 (858) 638-7708
Fax: +1 (858) 638-7727

© 2022 GlySens Incorporated. All Rights Reserved.
CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use.
GlySens® and Eclipse® are trademarks of GlySens Incorporated registered in the U.S. Patent and Trademark Office.
Terms of UsePrivacy Policy
usersheart-pulsepie-chartearth linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram